Versor Investments LP Has $226,000 Stock Holdings in Enhabit, Inc. (NYSE:EHAB)

Versor Investments LP grew its holdings in Enhabit, Inc. (NYSE:EHAB) by 135.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 28,900 shares of the company’s stock after buying an additional 16,600 shares during the quarter. Versor Investments LP’s holdings in Enhabit were worth $226,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Paradice Investment Management LLC increased its stake in shares of Enhabit by 12.8% in the fourth quarter. Paradice Investment Management LLC now owns 1,780,113 shares of the company’s stock valued at $13,903,000 after buying an additional 201,997 shares in the last quarter. Rhumbline Advisers increased its position in Enhabit by 2.8% in the fourth quarter. Rhumbline Advisers now owns 80,760 shares of the company’s stock worth $631,000 after purchasing an additional 2,211 shares during the period. Stoneridge Investment Partners LLC increased its position in Enhabit by 22.6% in the fourth quarter. Stoneridge Investment Partners LLC now owns 12,533 shares of the company’s stock worth $98,000 after purchasing an additional 2,308 shares during the period. Empowered Funds LLC increased its position in Enhabit by 5.0% in the fourth quarter. Empowered Funds LLC now owns 175,824 shares of the company’s stock worth $1,373,000 after purchasing an additional 8,448 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Enhabit by 37.8% in the third quarter. JPMorgan Chase & Co. now owns 305,245 shares of the company’s stock worth $2,411,000 after purchasing an additional 83,707 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages recently commented on EHAB. Leerink Partners reiterated a “market perform” rating and issued a $8.00 price objective (down from $8.50) on shares of Enhabit in a research report on Tuesday, November 19th. Jefferies Financial Group upgraded Enhabit from a “hold” rating to a “buy” rating and boosted their target price for the stock from $8.25 to $9.50 in a research report on Monday, December 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, Enhabit has an average rating of “Hold” and a consensus price target of $8.75.

Enhabit Price Performance

Enhabit stock opened at $8.49 on Wednesday. The firm has a market capitalization of $427.01 million, a P/E ratio of -3.66 and a beta of 1.83. Enhabit, Inc. has a 1 year low of $6.85 and a 1 year high of $11.74. The business has a 50-day moving average of $8.14 and a 200-day moving average of $7.90. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85.

Insider Activity

In other Enhabit news, Director Stuart M. Mcguigan acquired 15,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were acquired at an average price of $8.81 per share, for a total transaction of $132,150.00. Following the acquisition, the director now directly owns 46,810 shares of the company’s stock, valued at approximately $412,396.10. This trade represents a 47.15 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey Bolton acquired 4,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $8.69 per share, for a total transaction of $34,760.00. Following the acquisition, the director now directly owns 98,144 shares in the company, valued at $852,871.36. This represents a 4.25 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.90% of the stock is currently owned by company insiders.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.